Study Protocol of a Comprehensive Activity Promotion Program for the Prevention of Dementia: A Randomized Controlled Trial Protocol.

BACKGROUND: Several technical devices are available to monitor and promote changes in behavior toward higher activity. In particular, smartphones are becoming the primary platform for recognizing human activity. However, the effects of behavior change techniques that promote physical, cognitive, and social activities on incident dementia in older adults remain unknown. OBJECTIVES: This randomized controlled trial aims to examine the effects of behavior change techniques on the prevention of dementia among community-dwelling older adults using a smartphone as a behavior change tool. DESIGN: A randomized controlled trial. SETTING: Community in Japan. PARTICIPANTS: The study cohort comprises 3,498 individuals, aged ≥60 years, randomized into two groups: the smartphone group (n = 1,749) and the control group (n = 1,749). INTERVENTION: The smartphone group will be asked to use smartphone applications for at least 30 minutes daily to self-manage and improve their physical, cognitive, and social activities. The smartphone group will perform 60-minute group walking sessions using application-linked Nordic walking poles with cognitive stimulation twice a week during the intervention period. The walking poles are a dual-task exercise tool that works with a smartphone to perform cognitive tasks while walking, and the poles are equipped with switches to answer questions for simple calculation and memory tasks. The smartphone and control groups will receive lectures about general health that will be provided during the baseline and follow-up assessments. MEASUREMENTS: Incident dementia will be detected using cognitive tests (at baseline, after 15 months, and after 30 months) and by preparing diagnostic monthly reports based on data from the Japanese Health Insurance System. Participants without dementia at baseline who will be diagnosed with dementia over the 30-month follow-up period will be considered to have incident dementia. CONCLUSIONS: This study has the potential to provide the first evidence of the effectiveness of information communication technology and Internet of Things in incident dementia. If our trial results show a delayed dementia onset for self-determination interventions, the study protocol will provide a cost-effective and safe method for maintaining healthy cognitive aging.

Association of Daily Physical Activity with Disability in Community-Dwelling Older Adults With/Without Chronic Kidney Disease.

OBJECTIVES: Physical activity is recommended for disability prevention in the older adult population; however, the level of physical activity required for older adults with chronic kidney disease (CKD) remains unknown. This study aimed to examine the associations between daily physical activity and disability incidence in older adults with and without CKD to determine relevant daily physical activity levels. DESIGN: Prospective observational study. SETTING AND PARTICIPANTS: 3,786 community-dwelling older adults aged ≥65 years. MEASUREMENTS: Mean daily times spent in light- (LPA) and moderate-to-vigorous physical activity (MVPA) were measured using triaxial accelerometers. CKD was defined by a creatinine estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. Disability incidence was identified as long-term care insurance certification during a 60-month follow-up period. Associations between physical activity and disability incidence were examined using Cox proportional hazard models stratified by the CKD status. Non-linear and linear associations were tested using the restricted cubic spline. RESULTS: A total of 1,054 individuals were identified to have CKD. Disability incidence was higher in the CKD group than in the non-CKD group. The adjusted cox proportional hazard models indicated that a 10-minute increase in MVPA time was associated with lower disability incidence in the non-CKD group (hazard ratio [HR], 0.838; 95% confidence interval [CI]: 0.764-0.918) and the CKD group (HR, 0.859; 95% CI: 0.766-0.960). Linear associations were observed in MVPA for the non-CKD and CKD groups. CONCLUSION: Increasing MVPA was associated with lower disability incidence in older adults with and without CKD. These findings can help devise disability prevention strategies for older CKD patients.

Association between Non-Face-to-Face Interactions and Incident Disability in Older Adults.

OBJECTIVES: This observational prospective cohort study, conducted between September 2015 and February 2019, aimed to investigate the association between the incidence of disability and non-face-to-face interactions among community-dwelling older adults in Japan. DESIGN: Participants reported their interaction status using a self-report questionnaire. Face-to-face interactions comprised in-person meetings, while virtual interactions (e.g., via phone calls or emails) were defined as non-face-to-face interactions. We examined the relationship between their interaction status at baseline and the risk of disability incidence at follow-up. We also considered several potential confounding variables, such as demographic characteristics. SETTING: The National Center for Geriatrics and Gerontology-Study of Geriatric Syndromes. PARTICIPANTS: We included 1159 adults from Takahama City aged ≥75 years (mean age ± standard deviation = 79.5 ± 3.6 years). MEASUREMENTS: Interaction status was assessed using a self-reported questionnaire consisting of two sections (face-to-face and non-face-to-face interactions), and four questionnaire items. Based on the responses we categorized study participants into four groups: "both interactions," "face-to-face only," "non-face-to-face only," and "no interactions." RESULTS: Individuals with both kinds of interactions (49.3/1000 person-years) or only one kind of interaction (face-to-face = 57.7/1000 person-years; non-face-to-face = 41.2 person-years) had lower incidence of disability than those with no interactions (88.9/1000 person-years). Moreover, the hazard ratios adjusted for potential confounding factors for the incidence of disability in the both interaction, face-to-face-only, and non-face-to-face only groups were 0.57 (confidence interval = 0.39-0.82; p = 0.003), 0.66 (confidence interval = 0.44-0.98; p = 0.038), and 0.47 (confidence interval = 0.22-0.99; p = 0.048), respectively. CONCLUSION: Considering the interaction status of older adults in their day-to-day practice, clinicians may be able to achieve better outcomes in the primary prevention of disease by encouraging older adults to engage in any form of interaction, including non-face-to-face interactions.

Beneficial effect of adenosine during reperfusion following prolonged cardioplegic arrest.

STUDY OBJECTIVE: The aim of the study was to investigate the effect of reperfusion with adenosine after prolonged cardioplegic arrest in the isolated working rat heart. DESIGN: After 3 h or hypothermic (20 degrees C) ischaemic arrest with multidose (every 30 min) infusions of St Thomas's Hospital cardioplegic solution No 1, rat hearts were reperfused with either ordinary perfusion fluid (Krebs-Henseleit bicarbonate buffer) or with additional adenosine (1 mg x litre-1) for 15 min prior to assessing recovery of function. EXPERIMENTAL MATERIAL: Hearts (n = 10) in each group) were obtained from male rats weighing 250-300 g. MEASUREMENTS AND MAIN RESULTS: Mean coronary flow during the period of reperfusion was increased from 11.8(SEM 0.8) ml x min-1 with ordinary perfusate to 17(0.7) ml x min-1 with adenosine reperfusate (p less than 0.001). Mean recoveries of functional indices (as percent of preischaemic control values) in hearts receiving ordinary reperfusates v adenosine reperfusates were: peak aortic pressure 76.2(2.8)% upsilon 86.9(2.2)%, dP/dt 35.6(6.0)% upsilon 66.2(4.3)%, aortic flow 26.1(7.4)% upsilon 60.9(4.2)%, coronary flow 50.1(3.4% upsilon 75.6(3.6)%, and cardiac output 31.4(6.4)% upsilon 64.5(3.2)%. Recovery of all indices was significantly superior with adenosine than without (peak aortic pressure p less than 0.01, other indices p less than 0.001). A parallel series of experiments showed that the nucleotide content of both groups was similar at the end of the 15 min reperfusion period. CONCLUSIONS: Improvement in functional recovery occurs with low dose adenosine during reperfusion. This is likely to be due to an increase in coronary flow to the microvasculature rather than to an increase in intramyocardial ATP.

Mobilization of arachidonic acid between diacyl and ether phospholipids in rabbit alveolar macrophages.

The metabolism of 20:4 (arachidonic acid) in alkenylacyl, alkylacyl and diacyl lipid classes in choline glycerophospholipids (CGP) and ethanolamine glycerophospholipids (EGP) in rabbit alveolar macrophages was examined. [3H]20:4 was very rapidly incorporated into diacyl glycerophosphocholine (GPC). After the removal of free 20:4, the radioactivity was gradually lost from diacyl GPC. Concomitantly, the radioactivities in alkylacyl GPC and alkenylacyl glycerophosphoethanolamine (GPE) were increased, indicating that 20:4 was mobilized from diacyl GPC to alkylacyl GPC and alkenylacyl GPE. The mobilization was considered to be a 20:4-specific event. The gradual accumulation of 20:4 in ether phospholipids leads to a high abundance of 20:4 in these lipids. These results suggest metabolic relationships between 20:4 and ether phospholipids, including platelet-activating factor (PAF).

Functional and metabolic effects of adenosine in cardioplegia: role of temperature and concentration.

BACKGROUND: Addition of adenosine to cardioplegic fluid has been shown to improve myocardial tolerance to ischemia. This study was designed to investigate further this phenomenon to evaluate the dose-response and the temperature dependence of the effect of addition of adenosine to St. Thomas' Hospital cardioplegic solution. METHODS: The isolated working rat heart model was used in this study. After the assessment of control function, hearts (6 in each group) were subjected to infusions of cardioplegic solution containing 0.0 (control), 0.1, 5.0, 10.0 or 20.0 mmol/L adenosine followed by 3 hours of ischemic arrest at temperatures of 20 degrees C, 10 degrees C, or 4 degrees C with multidose (3 minutes every 30 minutes) cardioplegic infusion. RESULTS: After ischemic arrest at 20 degrees C, the recovery of cardiac output (expressed as percent of preischemic baseline) was 35.4 +/- 5.11 (control) 45.0 +/- 5.51 (0.1 mmol/L), 53.1 +/- 2.9 (5.0 mmol/L), 61.8 +/- 3.7 (10.0 mmol/L), and 57.6 +/- 2.3 (20.0 mmol/L). Hearts receiving 5.0 to 20.0 mmol/L adenosine had significantly greater recovery of cardiac output than control hearts. In its optimal concentration (10 mmol/L), adenosine improved the efficacy of the cardioplegic solution by almost 75%. Myocardial adenosine triphosphate content (expressed in mumol/g protein) was 4.7 +/- 0.5 (control), 4.9 +/- 1.4 (0.1 mmol/L), 8.1 +/- 0.7 (5 mmol/L), 12.5 +/- 2.0 (10 mmol/L), and 11.2 +/- 2.8 (20 mmol/L), at the end of ischemia and 13.9 +/- 0.2 (control), 13.1 +/- 1.7 (0.1 mmol/L), 18.0 +/- 2.0 (5 mmol/L), 18.6 +/- 1.2 (10 mmol/L), and 20.7 +/- 2.1 (20 mmol/L) at the end of reperfusion. Thus, the adenosine triphosphate content was higher (p < 0.05) in hearts receiving 5.0 to 20.0 mmol/L adenosine than in controls both at the end of ischemia and after reperfusion. Myocardial adenosine monophosphate level at the end of ischemia was inversely related to adenosine triphosphate level. Functional assessment of the effect of 10 mmol/L adenosine at 10 degrees C and 4 degrees C during arrest indicated attenuation of beneficial effects: adenosine improved function only by 17% at 10 degrees C, whereas at 4 degrees C the protective effect was not observed. CONCLUSIONS: These observations suggest that adenosine has the potential to enhance the efficacy of clinical cardioplegic arrest but the degree of improvement is lower at decreased temperature during ischemia. A principal mechanism of action of this modification of cardioplegic fluid appears to be through the inhibition of high-energy phosphate utilization immediately before or during ischemia.

Effect of cardioplegia infusion pressure on coronary artery endothelium and cardiac mechanical function.

OBJECTIVE: Monitoring of cardioplegia infusion pressure may be important, particularly in immature hearts and in hearts without coronary artery disease. We have investigated the effects of infusion pressure on the preservation of the isolated rat heart. METHODS: Hearts (five in each group) were subjected to a single (20 ml) infusion of St. Thomas' Hospital cardioplegic solution at pressures of 60, 120, 180 and 240 cmH2O (44-176 mmHg), followed by 30 min of hypothermic (20 degrees C) ischemia. RESULTS: Mean recovery of cardiac output (expressed as a percentage of its preischemic value) decreased with increasing infusion pressure: 96.1 +/- 0.6%, 87.3 +/- 2.1% (P < 0.05 vs. 60 cmH2O), 79.3 +/- 2.8% (P < 0.05 vs. 120 cmH2O), 72.0 +/- 3.0% (not significant vs. 180 cmH2O), respectively. Endothelial function, as assessed by pre- and post-ischemic ability to secrete NO in response to 5-hydroxytryptamine, remained relatively normal after infusion at 60 cmH2O, but changed from vasodilation to vasoconstriction after infusion at 240 cmH2O. Electron microscopy revealed mild endothelial damage after infusion at 240 cmH2O, which was greatly exacerbated by reperfusion and was accompanied by regions of myocyte damage compatible with reperfusion of unprotected myocardium. The relationship between cardioplegia infusion pressure and infusion time was not linear and implied that infusion pressures greater than 120 cmH2O caused vascular smooth muscle constriction. CONCLUSIONS: These results suggest that even mildly raised cardioplegia infusion pressures may be detrimental to cardiac preservation and the effects are possibly mediated through endothelial damage and pressure-induced coronary vasoconstriction.

Color changes in electronic endoscopic images caused by image compression.

In recent years, recording of color still images into magneto-optical video disks has been increasingly used as a method for recording electronic endoscopic images. In this case, image compression is often used to reduce the volume and cost of recording media and also to minimize the time required for image recording and playback. With this in mind, we recorded 8 images into a magneto-optical video disk in 4 image compression modes (no compression, weak compression, moderate compression, and strong compression) using the Joint Photographic Image Coding Experts Group (JPEG) system, which is a widely used and representative method for compressing color still images, in order to determine the relationship between the degree of image compression and the color information in electronic endoscopic images. The acquired images were transferred to an image processor using an offline system. A total of 10 regions of interest (ROls) were selected, and red (R), green (G), and blue (B) images were obtained using different compression modes. From histograms generated for these images, mean densities of R, G, and B in each ROI were measured and analyzed. The results revealed that color changes were greater for B, which had the lowest density, than for R or G as the degree of compression was increased.

[Pharmacological study of Mequitazine (LM-209). (V). Pharmacological actions of a main metabolite of LM-209, mequitazine sulfoxide (LM-209 SO) (author's transl)].

The pharmacological action of a main metabolite of Mequitazine (LM-209), Mequitazine sulfoxide (LM-209 SO), was compared with data on LM-209 to investigate whether LM-209 is metabolized in vivo to the active form and if it has pharmacological actions. In the excised ileum of guinea-pigs, the anti-histaminic and anti-cholinergic activities of LM-209 SO were about 1/8 and 1/20, respectively, of LM-209. The protective activity of LM-209 SO on sudden death induced by histamine in mice was about 1/2.5 of LM-209. Acute toxicity of LM-209 SO given orally to mice was 1/3 of LM-209. In the EEG of rabbits, LM-209 SO did not affect the spontaneous pattern or the arousal and recruiting responses. The mydriatic and local anesthetic activities of LM-209 SO were significantly less than those of LM-209. Thus, the pharmacological activities and toxicity of LM-209 SO were significantly less potent than those of LM-209.

Acute antihypertensive effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)-carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitrophen yl) octyl ester on conscious spontaneously hypertensive rats and renal hypertensive rats.

The acute antihypertensive effects of 3-pyridine carboxylic acid 5-[(cyclo-propylamino)carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitroph eny l) octyl ester (NP-252, CAS 132031-81-3) administered orally to conscious spontaneously hypertensive rats (SHRs) and renal hypertensive rats (RHRs) were evaluated using the impedance plethysmographical technique as a modified tail cuff method, and compared with those of nifedipine (NF). In the fitness test of this indirect method, the average value of blood pressure (BP) measured in 7 conscious SHRs was 201 +/- 6.9 mmHg. This value showed good correlation with that (201 +/- 8.8 mmHg) of systolic BP measured by the direct method in the same animals. In the comparative study of antihypertensive activities of the compounds on both models of hypertension using this method, NP-252 and NF dose-dependently lowered BP having a different peak time and restoration after dosing. Therefore, the antihypertensive activities were compared using a 20% effective dose (ED20) for producing hypotension, and the ED20 values of NP-252 and NF were 2.55 and 2.00 mg/kg in SHRs, and 1.25 and 0.67 mg/kg in RHRs, respectively. Moreover, the duration of actions of the compounds were evaluated by the simulated duration time (SDT) which was calculated from the peak time of BP-fall and the pharmacological half life time for the maximum BP-fall and the SDT values of NP-252 and NF were 1.85-4.70 and 0.90-0.75 h in SHRs, and 3.30-12.80 and 0.57-6.90 h in RHRs, respectively. Also, the BP-falls by the compounds were accompanied by an increase in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)

A New Endoscopic Technique for Examination of Esophageal Stenosis: The Funnel-shaped Transparent Cap Technique.

We have devised a funnel-shaped transparent cap for the endoscopic diagnosis and treatment of stenosis in the digestive tract. This funnel-shaped cap is made of highly transparent methacrylic resin. A 73-year-old woman with reflux esophagitis (categorized as grade D by the Los Angeles Classification) visited our hospital with the chief complaint of dysphagia. She was examined using an endoscope equipped with a transparent vinyl chloride hood at its tip. Many pieces of food were found to be trapped in the esophagus. These were removed using tripod forceps or aspirated into the hood. The internal diameter of the stenotic segment was as small as 1 or 2 mm, and it was difficult to advance the endoscope past the stenosis. The endoscope was withdrawn, and the attached hood was removed and replaced with a transparent cap. This provided clear visualization of the mucosal surface of the stenotic segment, which could not be examined using any conventional device, permitting the stenosis to be relieved.

Magnified examination of small colorectal polyps using a prototype electronic endoscope.

Magnifying electronic endoscopes are frequently used to evaluate the pit patterns of the colorectal mucosa, but such endoscopes suffer from a number of problems. For example, they tend to have long, hard tips and heavy controller sections. In addition, the magnified endoscopic images obtained are often quite coarse due to the small number of pixels in the charge-coupled device (CCD). As a result, at higher magnification ratios, the orientation of the field of view is easily lost. A newly developed prototype colorectal electronic endoscope (Toshiba Corporation, Tokyo) overcomes these problems. The length of the hard tip of the scope and the weight of the controller section are comparable to those of the TCE-3680MH (Toshiba Corporation). High-resolution magnified images can be obtained, because a 410,000-pixel CCD is employed. Two magnification methods are available, optical magnification and electronic zooming, permitting images to be magnified by a factor of up to 90-120 without losing the orientation of the field of view. This newly developed magnifying electronic endoscope was found to be very useful, allowing us to observe the pit patterns of the colorectal mucosa in 82 small colorectal polyps measuring 7 mm or less in diameter.

Cardiovascular effects of the new generation calcium antagonist 3-pyridine carboxylic acid 5-[(cyclopropylamino)carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitropheny l) octyl ester.

The cardiovascular effects of 3-pyridine carboxylic acid 5-[(cyclopropylamino)carbonyl]-1,4-dihydro-2,6-dimethyl-4-(2-nitro phenyl) oxtyl ester (NP-252, CAS 132031-81-3) were examined in anesthetized closed- or open-chest dogs and Langendorff perfused rabbit hearts, and compared with those of nifedipine (NF) and nicardipine (NC). In anesthetized closed- and open-chest dogs, NP-252 (i.v.) selectively increased vertebral and coronary blood flow with a fall in mean blood pressure (MBP). These effects were nearly equipotent with those of NF and NC, but more durable. A similar effect was obtained by intraduodenal administration of NP-252. Also, NP-252 (i.v.) decreased MBP, total peripheral resistance (TPR), left ventricular pressure and dLVP/dtmax while cardiac output (CO) and stroke volume (SV) increased without apparent changes in heart rate and myocardial contractility index. Decreases in MBP and TPR by NP-252 were equipotent with NF and NC, whereas increases in CO and SV were more potent than those of the two drugs. These actions of NP-252 were longer than those of the reference agents. Further, in perfused rabbit hearts, NO-252 increased coronary perfusion flow (CPF), accompanying a slight negative inotropy. Its effect in CPF was equipotent with NF and 2 times less than that of NC, however the duration was much longer than those of the reference drugs. On the other hand, the negative inotropic effect of NP-252 was less than NF, but greater than that of NC. In the preparations controlled by pacing, NP-252 and NF lengthened atrio-His bundle conduction time, without affecting His bundle-ventricular conduction time. Lengthening effect of NP-252 was about 4 times less than that of NF. These results suggest that NP-252 acts more selectively on vascular smooth muscle than cardiac muscle, and has almost equipotent but markedly longer vasodilating actions as compared to NF and NC. It may be expected that NP-252 is a new generation of tissue specific and long acting Ca2+ antagonist.

[Pharmacological study of mequitazine (LM-209). (IV). General pharmacological action (author's transl)].

The general pharmacological actions of LM-209 were studied in rats, cats, dogs, guinea pigs and mice and the findings were compared with data on clemastine fumarate (CL). LM-209 but not CL produced a slight increase in pulse pressure and tachycardia. Inhibitory effects of LM-209 against contraction of the vas deferens and nictitating membrane, mainly dominated by sympathetic innervation, were remarkably less potent than CL. Inhibitory effects of LM-209 in the gastrointestinal tract were slightly more potent than CL. LM-209 accelerated norepinephrine-induced pressor reaction, while CL inhibited these effects at the dose level inhibiting histamine-induced depressor reaction. At the oral dose level showing anti-histaminic and anti-allergic actions, LM-209 but not CL had slight anti-tussive action, in an experimental model. Local anesthetic action of LM-209 was slightly more potent than that of lidocaine. LM-209 showed the same properties and potencies as CL, in most of the general pharmacological experiments.

Interrelationship between serum and fecal sterols.

Seven healthy volunteers and 3 hospitalized patients were given the same diet for 6 days. The mean intake of cholesterol was 359 mg/day. There was a large difference in the fecal amount of cholesterol and coprostanol among the subjects. The ratio of coprostanol/cholesterol ranged from 0.01 to 4.27. The subjects whose feces contained smaller amount of coprostanol excreted larger amounts of beta-sitosterol and crude fiber, suggesting that the various activities of intestinal flora were lower than the other subjects. The difference in the activity of intestinal flora to convert cholesterol into coprostanol was ascertained by incubating the feces anaerobically with egg yolk in vitro. It was also demonstrated that cholesterol was synthesized de novo and the amount corresponded to 0.1-0.6 g/day. The amounts of sterols in the feces of the other 17 hospitalized patients were also determined and there was an inverse relationship between the serum cholesterol and coprostanol/cholesterol ratio in the feces. These results suggested that the conversion of cholesterol into coprostanol by the intestinal flora might have an important role in the regulation of serum cholesterol level.

Prolonged cardiac preservation. Evaluation of the University of Wisconsin preservation solution by comparison with the St. Thomas' Hospital cardioplegic solutions in the rat.

The University of Wisconsin solution differs from other types of solutions used for organ preservation because it contains high-energy phosphate precursors (adenosine and phosphate), impermeants (lactobionate and raffinose), an oncotic agent (pentafraction), and antioxidants (allopurinol and glutathione). These components have the potential to enhance the preservation of ATP, reduce intracellular and extracellular edema, and attenuate free-radical-mediated injury. The University of Wisconsin solution has been demonstrated to enhance and extend the preservation of the liver, pancreas, and kidney, but its potential role in the heart remains unproven. We have evaluated the University of Wisconsin solution (Du Pont) by comparing it with the St. Thomas' Hospital cardioplegic solutions No. 1 and No. 2 (Plegisol), which are used in Europe and the United States for routine cardiac surgery and transplantation. For each solution, 10 isolated working rat hearts were arrested by 10 ml of the solution (at 4 degrees C) and then maintained immersed in the same solution for 4 hours at 4 degrees C. Mean recovery of functional indexes (expressed as a percentage of their preischemic control values) after use of the University of Wisconsin solution were as follows: peak aortic pressure, 90.6 +/- 1.0; dP/dt, 71.5 +/- 5.5; aortic flow, 81.6 +/- 4.7; coronary flow, 87.5 +/- 3.5; and cardiac output, 82.6 +/- 3.5. In contrast, the mean recoveries after St. Thomas' Hospital solution No. 1 were as follows: peak aortic pressure, 82.8 +/- 1.3; dP/dt, 49.7 +/- 3.0; aortic flow, 58.4 +/- 5.3; coronary flow, 79.6 +/- 5.9; and cardiac output, 63.0 +/- 4.9. In contrast still, mean recoveries after St. Thomas' Hospital solution No. 2 were as follows: peak aortic pressure, 83.1 +/- 1.2; dP/dt, 40.7 +/- 6.1; aortic flow, 37.0 +/- 5.1; coronary flow, 65.8 +/- 3.6; and cardiac output, 43.1 +/- 5.6. The recovery of all indexes were significantly superior (p less than 0.005) after preservation with University of Wisconsin solution compared with either of the St. Thomas' Hospital solutions.(ABSTRACT TRUNCATED AT 250 WORDS)